Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Randomized, Active-controlled Clinical Study to Compare the Efficacy and Safety of Different Combination Regimens of JDB0131 Benzenesulfonate Tablets With Delamanid in Patients With Rifampin-resistant Tuberculosis (JD-RISE)

NCT07170800 is registered in ClinicalTrials.gov with WestVac Biopharma Co., Ltd. as lead sponsor.

NCT NCT07170800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07170800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Randomized, Active-controlled Clinical Study to Compare the Efficacy and Safety of Different Combination Regimens of JDB0131 Benzenesulfonate Tablets With Delamanid in Patients With Rifampin-resistant Tuberculosis (JD-RISE)
Lead sponsor
WestVac Biopharma Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
September 19, 2025
Completion date
September 4, 2026
Enrollment
60 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

multidrug resistant pulmonary tuberculosis, rifampicin-resistant tuberculosis, tuberculosis